in 1985, de clercq and holý described the activity of pmpa against hiv in cell culture. shortly thereafter, a collaboration with the biotechnology company gilead sciences led to the investigation of pmpa's potential as a treatment for hiv infected patients. in 1997 researchers from gilead and the university of california, san francisco demonstrated that tenofovir exhibits anti-hiv effects in humans when dosed by subcutaneous injection.